Evotec Achieves $10M Milestone in Collaboration with Bristol Myers Squibb

Evotec SE has announced a significant milestone in its collaboration with Bristol Myers Squibb (BMS) after the first patient dosing in a Phase 1 clinical study of BMS-986506. This trial aims to evaluate the treatment's efficacy in advanced clear cell renal cell carcinoma, the most common form of kidney cancer. This marks a crucial step in their protein degradation collaboration, signifying a transition to clinical applications for their oncology platform.

The study exemplifies the partnership's innovative approach, employing Evotec's multi-omics screening and AI-driven capabilities to design drugs that selectively degrade disease-causing proteins. As part of this progression, Evotec will receive a $10 million milestone payment from BMS.

Dr. Cord Dohrmann of Evotec noted the potential of 'molecular glues' to meet unmet medical needs in oncology, highlighting the strategic importance of this collaboration. Initiated in 2018 and expanded in 2022, the partnership aims to develop pioneering molecular glue degraders across various therapeutic areas.